	US 12,133,867 B2
	Universal anti-CD22 chimeric antigen receptor engineered immune cells
Julianne Smith, New York, NY (US); Phillippe Duchateau, Draveil (FR); and Murielle Derrien, Paris (FR)
Assigned to CELLECTIS SA, Paris (FR)
Filed by CELLECTIS SA, Paris (FR)
Filed on Dec. 21, 2023, as Appl. No. 18/393,322.
Application 18/393,322 is a continuation of application No. 16/498,899, granted, now 11,944,643, previously published as PCT/EP2018/058367, filed on Mar. 30, 2018.
Claims priority of application No. 201770239 (DK), filed on Mar. 31, 2017; application No. 201770240 (DK), filed on Mar. 31, 2017; and application No. 201770542 (DK), filed on Jun. 30, 2017.
Prior Publication US 2024/0189354 A1, Jun. 13, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 35/17 (2015.01); A61K 31/365 (2006.01); A61K 39/395 (2006.01); A61P 35/02 (2006.01); C07K 14/705 (2006.01); C07K 14/725 (2006.01); C07K 16/28 (2006.01)

CPC A61K 35/17 (2013.01) [A61K 31/365 (2013.01); A61K 39/39558 (2013.01); A61P 35/02 (2018.01); C07K 14/7051 (2013.01); C07K 14/70517 (2013.01); C07K 14/70578 (2013.01); C07K 16/2803 (2013.01); C07K 2317/34 (2013.01); C07K 2317/53 (2013.01); C07K 2317/622 (2013.01)]

24 Claims

1. An engineered human Universal Chimeric Antigen Receptor (CAR) T Cell specific for CD22 (UCART22) comprising a Chimeric Antigen Receptor specific for CD22 (anti-CD22 CAR) and a safety switch, wherein:

(a) said anti-CD22 CAR comprises amino acid residues 22-490 of SEQ ID NO: 15, and

(b) said safety switch comprises a sequence of SEQ ID NO: 60, and wherein the UCART22 comprises an inactivated CD52 gene and an inactivated T cell receptor alpha constant (TRAC) gene.